Effective antitumor activity of paclitaxel-loaded poly (epsilon-caprolactone)/pluronic F68 nanoparticles after intratumoral delivery into the murine breast cancer model.
A paclitaxel-loaded poly (epsilon]-caprolactone)(PCL)/pluronic F68 (F68) nanoparticle formulation was prepared as an intratumoral delivery system to assess its potential for future neoadjuvant chemotherapy application in the treatment of breast cancer. Paclitaxel-loaded nanoparticles were prepared by a solvent evaporation method using the self-synthesized PCL/F68 compound. Prepared nanoparticles were spherical with a rough, porous surface. As described in our earlier study, F68 was incorporated into the PCL matrix as both a pore-forming agent and to enhance drug release from the particles. A murine breast cancer model has shown that when using equivalent paclitaxel doses, paclitaxel-loaded PCL/F68 nanoparticles administered by a single intratumoral injection were more efficient in impeding tumor development than conventional paclitaxel injections administered by multiple intraperitoneal injections. In conclusion, paclitaxel-loaded PCL/F68 nanoparticles can be delivered intratumorally and they effectively prevent tumor cell growth and establishment in a localized area. This treatment shows promise as a future neoadjuvant chemotherapy application in the treatment of breast cancer.
Ma
Guilei
G
The Tianjin Key Laboratory of Biomaterials, The Institute of Biomedical Engineering, Peking Union Medical College and Chinese Academy of Medical Sciences, Tianjin, China.
Yang
Jing
J
Zhang
Linhua
L
Song
Cunxian
C
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D016503:Drug Delivery Systems; D005260:Female; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D015674:Mammary Neoplasms, Animal / Q000188:drug therapy* / Q000473:pathology; D051379:Mice; D053758:Nanoparticles / Q000008:administration & dosage*; D017239:Paclitaxel / Q000008:administration & dosage*; D020442:Poloxamer / Q000008:administration & dosage*; D011091:Polyesters / Q000008:administration & dosage*
D000970:Antineoplastic Agents; D011091:Polyesters; D020442:Poloxamer; C016240:polycaprolactone; D017239:Paclitaxel